Drugs / VNX-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06533579 | May 2025 → Jun 2027 expected | B-cell acute lymphoblastic leukemia, Burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma +6 | Vironexis Biotherapeutics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-09-12 | Vironexis Biotherapeutics Inc. | Regulatory Vironexis Biotherapeutics Launches with FDA Clearance of IND Application for First-Ever Clinical Trial of an AAV-delivered Cancer Immunotherapy vironexis.com ↗
The company has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for VNX-101, its first gene therapy product candidate, for the treatment of CD19+ acute lymphoblastic leukemia. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-21 | Vironexis Biotherapeutics Inc. | Vironexis Announces Complete and Durable Responses in Relapsed/Refractory ALL Patients Treated with VNX-101 vironexis.com ↗ |
| 2024-09-12 | Vironexis Biotherapeutics Inc. | Vironexis Biotherapeutics Launches with FDA Clearance of IND Application for First-Ever Clinical Trial of an AAV-delivered Cancer Immunotherapy vironexis.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VNX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06533579 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “VNX-101 is an investigational adeno-associated virus (AAV) gene therapy” NCT06533579 ↗ |